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ABSTRACT 
Objective: Metoprolol succinate is a Beta 1 selective antagonist used as an Anti hypertensive, Anti angina, Anti arrhythmic. The aim of present 
investigation was to develop matrix tablets of Metoprolol succinate using different polymers.  
Methods: Metoprolol succinate matrix tablets were prepared by direct compression and wet granulation method using different polymers. All the 
formulations were evaluated for weight variation, thickness, hardness, friability and dissolution. 
Results: It has been studied that a matrix tablet containing hydroxyl propyl methyl cellulose polymers for oral controlled delivery of Metoprolol 
succinate has been formulated with greater significance; hence it was decided to check the in-vitro drug-polymer study in formulating a sustained 
release tablet for Metoprolol succinate. All the formulations are prepared by using polymers include HPMC K15M, HPMC K100M, Ghatti gum, 
Sodium CMC, Pectin. All the formulation is subjected to invitro dissolution studies. 
Conclusion: Among all these formulations F-11 is optimized. This formulation containing 50mg of drug, 150mg of HPMC K15M, 3mg of Mg stearate, 
3mg of talc, and 69mg of MCC. As the result of this study it may conclude that the formulation meet the needed theoretical drug release profile and 
has the sustain action i.e., retarding the drug release so the release is for a long time and thus more bio availability. 
Keywords: Metoprolol succinate, Sustained release Matrix tablets, Direct compression, Wet granulation method. 
 
INTRODUCTION 
Oral route is considered most natural, uncomplicated, convenient 
and safe due to its ease of administration, patient acceptance, and 
cost effective manufacturing process. Oral drug delivery is the most 
widely utilized route of administration among all the routes that 
have been explored for the systemic delivery of drug via 
pharmaceutical products of different dosage form. 
The sustained release oral dosage forms have been demonstrated to 
improve therapeutic efficacy by maintaining steady state drug 
plasma concentration. Various types of modified release 
formulations have been developed to improve the patient 
compliance and also clinical efficacy of the drug. Hydroxypropyl 
methyl cellulose (Hypromellose, HPMC) polymers have been widely 
studied for their application in oral sustained release formulations. 
Such hydrophilic polymers are most popular because of their 
flexibility to get a desirable drug release profile, cost effectiveness 
and broad regulatory acceptance [1]. HPMC has always been a first 
choice for formulation of hydrophilic matrix systems, because of 
providing robust mechanism, choice of viscosity grades, nonionic 
nature, consistent reproducible release profiles, cost effectiveness 
and utilization of existing conventional equipment and methods. 
HPMC most widely used as the gel forming agent in the formulations 
of solid, liquid, semisolid and controlled release dosage forms. The 
adjustment of the polymer concentration, the viscosity grades and 
the addition of different types and levels of excipients to the HPMC 
matrix can modify the drug release rates. The other advantages of 
sustained release dosage forms are patient compliance, reduction of 
local and systemic side effects, minimization of peaks and valleys in 
drug blood levels [2]. 
Metoprolol is a β1 
MATERIALS AND METHODS 
selective antagonist with antihypertensive 
activity. It is readily absorbed from the gastrointestinal tract with 
oral bioavailability of about 38% and a plasma elimination half-life 
ranging from 1.5 to 2 hours. Administration of Metoprolol succinate 
in a sustained release dosage form would be more desirable by 
maintaining the plasma concentrations of the drug well above the 
therapeutic concentration. 
Materials 
Metoprolol succinate was obtained from Dr.Reddy’s Laboratories 
Ltd, Hyderabad. HPMC grades were received from yarrow chem 
products, Mumbai. Other materials were purchased from Signet 
Chem, Mumbai, India. 
Methodology 
Preformulation Studies 
Standardization of Metoprolol succinate by UV-Visible 
spectrophotometry in 0.1 N HCl Solution 
Preparation of stock solution 
Stock solution 100µg/ml of Metoprolol succinate was prepared in 
0.1N Hcl solution. This solution was approximately diluted with 0.1N 
Hcl to obtain a concentration of 10µg/ml. The resultant solution was 
scanned in range of 200- 400nm using UV double beam 
spectrophotometer (Lab India UV-3000+). 
Standard calibration of Metoprolol succinate in 0.1N HCl 
100mg of Metoprolol succinate was accurately weighed and 
dissolved in100ml of 0.1N HCl to obtain a concentration of 
1000µg/ml. From the above 10ml was withdrawn and diluted to 
100ml to obtain a concentration of 100µg/ml. From this stock 
solution aliquots of 0.5ml, 1ml, 1.5ml, 2ml, 2.5ml and 3.0ml were 
diluted in 10ml volumetric flask with phosphate buffer to give 
concentrations in range of 5µg/ml to 30µg/ml respectively, 
absorbance was measured at 224nm. 
In pH 6.8 Buffer 
Preparation of stock solution 
Stock solution 100µg/ml of Metoprolol succinate was prepared in 
phosphate buffer of pH 6.8. This solution was approximately diluted 
with phosphate buffer of pH 6.8 to obtain a concentration of 
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10µg/ml. The resultant solution was scanned in range of 200- 
400nm using UV double beam spectrophotometer (Lab India UV-
3000+). 
Standard calibration of Metoprolol succinate in phosphate 
buffer of pH 6.8 
100mg of Metoprolol succinate was accurately weighed and 
dissolved in100ml of pH 6.8 phosphate buffer to obtain a 
concentration of 1000µg/ml. From the above 10ml was withdrawn 
and diluted to 100ml to obtain a concentration of 100µg/ml. From 
this stock solution aliquots of 0.5ml, 1ml, 1.5ml, 2ml, 2.5ml and 
3.0ml were diluted in 10ml volumetric flask with phosphate buffer 
to give concentrations in range of 5µg/ml to 30µg/ml respectively, 
absorbance was measured at 228nm. 
Drug- Excipient Compatibility by FTIR studies 
In the preparation of SR tablet, drug and polymer may interact as 
they are in close contact with each other, which could lead to 
instability of drug. Preformulation studies  regarding drug-polymer 
interactions are therefore very critical in selecting appropriate 
polymers. FT-IR spectroscopy (Agilent Technologies) was employed 
to ascertain the compatibility between Metoprolol succinate and 
selected polymers. The individual drug and drug with excipients 
were scanned separately. 
Procedure 
Potassium bromide was mixed with drug and polymer in the ratio 
of 100:1 and pellet was prepared using KBr pellet press and 
spectrum was taken using FTIR (Agilent Technologies). FT-IR 
spectrum of Metoprolol succinate was compared with spectrum of 
Metoprolol succinate and polymer. Disappearance of Metoprolol 
succinate peaks or shifting of peak in any of the spectra was 
studied.  
Angle of repose 
The angle of repose was determined by the funnel method. The 
accurately weighed powder was taken in a funnel. The height of the 
funnel was adjusted in such a way that the tip of the funnel just 
touched the apex of the heap of the powder. The powder was 
allowed to flow through the funnel freely onto the surface. The 
diameter of the powder cone was measured. The angle of repose 
was calculated using the following equation. 
Tan Ѳ= h/r 
Where ‘h’ and ‘r’ are the height and radius respectively of the powder 
cone 
Carr’s compressibility index 
The Carr’s compressibility Index was calculated from Bulk density 
and tapped density of the blend. A quantity of 2g of blend from each 
formulation, filled into a 10mL of measuring cylinder. Initial bulk 
volume was measured, and cylinder was allowed to tap from the 
height of 2.5cm. The tapped frequency was 25±2 per min to measure 
the tapped volume of the blend. The bulk density and tapped density 
were calculated by using the bulk volume and tapped volume. 
Carr’s compressibility index was calculated by using following 
formula: 
Carr’s compressibility index (%) = [(Tapped density-Bulk 
density) X100]/Tapped density ….. Eqn. (2) 
Bulk Density (BD) 
An accurately weighed powder blend from each formula was lightly 
shaken to break any agglomerates formed and it was introduced in 
to a measuring cylinder. The volume occupied by the powder was 
measured which gave bulk volume. The bulk densities (BD) of 
powder blends were determined using the following formula. 
Bulk density = Total weight of powder / Total volume of powder 
Tapped bulk density (TBD)  
An accurately weighed powder blend from each formula was lightly 
shaken to break any agglomerates formed and it was introduced into 
a measuring cylinder. The measuring cylinder was tapped until no 
further change in volume was noted which gave the tapped volume. 
The tapped bulk densities (TBD) of powder blends were determined 
using the following formula. 
TBD= Total weight of powder / Total volume of tapped powder 
Preparation of tablets 
Different tablets formulations were prepared by direct compression 
and wet granulation technique.  
Direct compression method: All powders were passed through 60 
mesh. Required quantities of drug and polymers were mixed 
thoroughly Magnesium stearate was added as lubricant. Talc was 
used as glidant. Micro crystalline cellulose was used as diluent. 
Finally the powder mix was subjected to compression after mixing 
uniformly in a polybag. Prior to compression, the blends were 
evaluated for several tests. In all formulations, the amount of the 
active ingredient is equivalent to 50mg of Metoprolol succinate. 
Wet granulation method: All the powders were passed through 80 
mesh. Required quantities of all ingredients were mixed thoroughly 
and a sufficient volume of granulating agent was added slowly. After 
enough cohesiveness was obtained, the mass was sieved through 
22/44 mesh. The granules were dried at 40 C for 12hrs. Once, dry 
the granules retained on 44 mesh were mixed with 10% of fine 
granules that passed through 44 mesh. Talc and magnesium stearate 
were added as glidant and lubricant. 
Evaluation of tablets 
The weight of tablets was evaluated on 20 tablets using an electronic 
balance. Friability was determined using 6 tablets in Roche friability 
tester at 25rpm. Hardness of the tablets was evaluated using an 
Monsanto hardness tester. The hardness of all the formulation was 
between 4-6kg/cm2
In vitro drug release studies from the prepared matrix tablets were 
conducted using USP type II apparatus at 37°C at 50rpm. Dissolution 
mediums used were 900mL of 0.1N HCl and phosphate buffer of pH 
6.8. The release rates from matrix tablets were conducted in HCl 
solution (pH 1.2) for 2h and changed to phosphate buffer (pH 6.8) 
for further time periods. The samples were withdrawn at desired 
time periods from dissolution media and the same were replaced 
with fresh dissolution media of respective pH. The samples were 
analyzed by UV-Visible Spectrophotometer (Lab India 3000+). The 
amounts of drug present in the samples were calculated with the 
help of appropriate calibration curves constructed from reference 
standards. Drug dissolved at specified time periods was plotted as 
percent release versus time curve [4]. 
. 
In vitro dissolution studies 
 
Table 1: Formulations Containing HPMC K100M, HPMC K15M ( Wet granulation) 
Ingredients F1 F2 F3 F4 
Metoprolol succinate 50 50 50  50 
HPMCK100M 100 150 -  - 
HPMCK15M - - 100 150 
PVP K30 10 10 10 10 
Mg Stearate 3 3 3 3 
Talc 3 3 3 3 
MCC 109 59 109  59 
Total 275 275 275  275 
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Table 2: Formulations Containing HPMC K100M, HPMC K15M, Sodium CMC, Ghatti gum (Direct compression) 
Ingredients F5 F6 F7 F8 F9 F10 F11 
Drug 50 50 50 50 50 50 50 
HPMCK100M 100 150 - - - - - 
HPMC K15M - - - - - 100 150 
Sodium CMC - - 100 150 - - - 
Ghattigum - - - - 100 - - 
Mg Stearate 3 3 3 3 3 3 3 
Talc 3 3 3 3 3 3 3 
MCC 119 69 119 69 119 119 69 
Total 275 275 275 275 275 275 275 
 
Data Analysis (Curve Fitting Analysis) 
To analyze the mechanism of the drug release rate kinetics of the 
dosage form, the data obtained were graphed as: 
1. Cumulative percentage drug released Vs Time (In-vitro drug release 
plots) 
2. Cumulative percentage drug released Vs Square root of time (Higuchi’s 
plots) 
3. Log cumulative percentage drug remaining Vs Time (First order plots) 
4. Log percentage drug released Vs Log time (Peppas plots) 
Zero order 
 
Where K0 - 
t - is the time in hrs. 





K - is the first order constant 
 - is the initial concentration of drug, 




K- is the kinetic constant and  
 - is the amount of the release drug in time t, 





 - represents amount of the released drug at time t,  
∞
K- is the diffusional characteristic of drug/ polymer system constant  
 is the overall amount of the drug (whole dose) released after 12 hrs  
n- is a diffusional exponent that characterizes the mechanism of 
release of drug.  
The value of n indicates the drug release mechanism related to the 
geometrical shape of the delivery system, if the exponent n = 0.5, 
then the drug release mechanism is Fickian diffusion.  
If n < 0.5 the mechanism is quasi-Fickian diffusion, and 0.5 < n < 1.0, 
then it is non-Fickian or anomalous diffusion and when n = 1.0 
mechanism is non Fickian case II diffusion, n> 1.0 mechanism is non 
Fickian super case II [3]. 
RESULTS AND DISCUSSION 
Preformulation characteristics 
The drug Metoprolol succinate was standardized by UV method in 
0.1N HCl and pH 6.8 Buffer separately. The lambda max were 224nm 
and 228 nm in 0.1N HCl and pH 6.8 buffer respectively and the 




 of Metoprolol succinate in 0.1 N HCl (224nm) 
Fig. 2: Calibration curve of Metoprolol Succinate in 0.1N HCL 
 
Physical characteristics of blends and tablets 
The blends of different formulations were evaluated for angle of 
repose, Carr’s compressibility index etc., The results of Angle of 
repose and Carr’s compressibility Index (%) ranged from 16-28 and 
14-16, respectively which showed that blends from all the 
formulations having good flow property. The hardness and 
percentage friability ranged from 4-5kg/cm2 and 0.18-0.35% 
respectively.  
 
Table 3: Absorbences of Metoprolol Succinate in 0.1N HCL 
S. No. Concentration Absorbance  
1 5 0.212 
2 10 0.340 
3 15 0.431 
4 20 0.576 
5 25 0.694 
6 30 0.795 
7 35 0.853 
 
Table 4: Absorbences of metoprolol succinate in 6.8 ph 
phosphate buffer 
S. No. Concentration Absorbance (nm) 
1 5 0.169 
2 10 0.248 
3 15 0.414 
4 20 0.498 
5 25 0.634 
6 30 0.696 
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Fig. 4: Calibration curve of Metoprolol Succinate in 6.8 pH 
Phosphate buffer 
Drug: Excipient Compatibility studies- FTIR 
Drug-Excipient compatibility studies by FTIR revealed no 
interaction between drug and the polymers used in the formulation 
thus showing compatibility. 
In vitro dissolution studies 
 of metoprolol succinate in pH 6.8 buffer (228nm) 
[ 
Sustained release tablets of Metoprolol succinate were prepared by 
using HPMC polymers. The release rate of Metoprolol succinate 
mainly controlled by the hydration and swelling properties of HPMC 
which forms a gel layer that controls the water penetration and drug 
diffusion. The effect of polymer concentration on drug release could 
be clearly seen from the variation of the dissolution profiles. The 
drug release data of dissolution studies of formulation (F1 to F4) 
containing HPMC K100M & HPMC K15M (wet granulation method), 
F5 to F6 containing HPMC K100M (By direct compression method), 
F7 to F8 containing Sodium CMC, F9 containing ghatti gum and F10 
to F11 containing HPMC. When cumulative % drug release plotted 
versus time was observed that, for three of the polymers used, an 
increase in polymer concentration induce a decrease in the release 
rate. Formulation F11 containing HPMC K100 (1:3) met the needed 
theoretical drug release profile and has the sustain action i.e., 
retarding the drug release so the release is for a long time and thus 
more bioavailability; for these reasons, it was considered the best 
formulation among all the formulations of this series. 
 
 
Fig. 5: FTIR spectra of pure Drug 
 
 
Fig. 6: FTIR spectra of pure Drug, polyme
 
Table 5: Pre compression parameters 








Angle of repose 
F1 0.427±0.003 0.577±0.06 1.35 30.7 31.2±1.001 
F2 0.43±0.036 0.663±0.04 1.54 35.6 31.6±0.5 
F3 0.412±0.003 0.646±0.03 1.56 32.75 35.8±0.95 
F4 0.423±0.006 0.623±0.04 1.47 33.8 32.6±0.5 
F5 0.435±0.001 0.634±0.06 1.45 32.4 33.4±0.4 
F6 0.421±0.001 0.652±0.05 1.54 33.4 35.9±0.458 
F7 0.423±0.003 0.632±0.09 1.49 33.9 32.3±0.3 
F8 0.462±0.004 0.648±0.04 1.40 34.7 34.2±0.34 
F9 0.453±0.003 0.655±0.03 1.44 29.4 32.5±0.5 
F10 0.441±0.002 0.648±0.06 1.46 21.4 36.8±0.529 
F11 0.437±0.002 0.638±0.05 1.45 32.1 33.1±0.624 
 
Table 6: Post compression parameters 
Formulation code Hardness Friability Weight variation Thickness 
F1 5.3  0.09 275  2.5 
F2 5.0  0.06 275 3.0 
F3 4.8  0.06 274  2.8 
F4 5.1  0.11 274  2.0 
F5 5.0  0.07 275 2.5 
F6 4.9  0.04 275  2.5 
F7 5.0  0.08 275 2.5 
F8 5.0  0.02 276  3 
F9 4.7  0.05 275 2.5 
F10 4.7  0.04 275 2.5 
F11 4.8  0.06 274  2.5 
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Fig. 7: Dissolution graphs of F1, F2, F3, F4 Formulations 
 
 
Fig. 8: Dissolution graphs of F5, F6, F7, F8, F9, F10, F11 
Formulations 









Metoprolol succinate sustained release matrix tablets were 
prepared successfully using HPMC polymer of different viscosity. 
According to in vitro release studies, the release rate was decreased 
with increasing viscosity and amount of polymer. The results of the 
study clearly demonstrated that HPMC matrix tablet formulation is 
an effective and promising drug delivery system for once daily 
administration of Metoprolol succinate.The analysis of the release 
profiles in the light of distinct kinetic models (zero order, first order, 
Higuchi, Korsmeyer Peppas) led to the conclusion that, the drug 
release characteristics from HPMC polymer matrices follows 
Korsmeyer-peppas kinetics and the mechanism of drug release was 
both diffusion and erosion.  
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